// App-Quantinova.ai

3038 : Association of response to programmed death 1 receptor or ligand (PD1/PDL1) blockade with immune-related gene expression profiling across three cancer-types.

Researchers

Presenter

  • Alejandro Navarro

Principal Investigators

  • Ana Arance

  • Noemi Reguart

  • Laia Pare

  • Patricia Galvan

  • Alex Martinez Marti

  • Paolo Nuciforo

  • Nuria Pardo Aranda

  • Susana Cedres Perez

  • Lydia Gaba

  • Ivan Victoria

  • Nuria Vinolas

  • Ana Vivancos

  • Aleix Prat

  • Enriqueta Felip

Medical Centers

  • Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain

  • Translational Genomics and Targeted Therapeutics in Solid Tumors Lab (IDIBAPS), Medical Oncology. Hospital Clinic Barcelona, Barcelona, Spain

  • Medical Oncology Department Vall d Hebron Institute of Oncology-Vall D'Hebron University Hospital, Barcelona, Spain

  • Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Medical Oncology Department Vall d Hebron Institute of Oncology-Vall D'Hebron University Hospital, Barcelona, Spain

  • Medical Oncology Department Vall d Hebron Institute of Oncology-Vall D'Hebron University Hospital, Barcelona, Spain

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Department of Pathology, Hospital Clinic de Barcelona, Barcelona, Spain

  • Cancer Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Medical Oncology, Hospital del Mar, Barcelona, Spain

  • Vall d'Hebron University Hospital, Barcelona, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

  • Melanoma

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

  • Atezolizumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved